Shanghai OPM Biosciences Co., Ltd. (SHA:688293)
China · Delayed Price · Currency is CNY 79.61
+5.05 (6.77%)
At close: Sep 30, 2026
Shanghai OPM Biosciences Revenue
Shanghai OPM Biosciences had revenue of 271.53M CNY in the quarter ending June 30, 2026, with 188.65% growth. This brings the company's revenue in the last twelve months to 630.86M, up 90.37% year-over-year. In the year 2025, Shanghai OPM Biosciences had annual revenue of 354.91M with 19.40% growth.
Revenue (ttm)
630.86M
Revenue Growth
+90.37%
P/S Ratio
17.94
Revenue / Employee
6.18M
Employees
102
Market Cap
11.32B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 354.91M | 57.67M | 19.40% |
| Dec 31, 2024 | 297.24M | 54.12M | 22.26% |
| Dec 31, 2023 | 243.12M | -51.24M | -17.41% |
| Dec 31, 2022 | 294.37M | 81.68M | 38.41% |
| Dec 31, 2021 | 212.68M | 87.71M | 70.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.19B |
| Tibet Cheezheng Tibetan Medicine | 2.22B |
| Inner Mongolia Furui Medical Science | 1.64B |
| Jiangxi Fushine Pharmaceutical | 1.56B |
| Jinyu Bio-technology | 1.53B |
| Hualan Biological Vaccine | 1.19B |
| Mabwell (Shanghai) Bioscience | 873.99M |
| Chengdu Olymvax Biopharmaceuticals | 759.63M |